Literature DB >> 18430851

Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas.

Hyunchul Rhim1, Mi Hee Lee, Young-Sun Kim, Dongil Choi, Won Jae Lee, Hyo K Lim.   

Abstract

OBJECTIVE: The objective of our study was to evaluate the feasibility rate and the reasons for infeasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas (HCCs) at planning sonography.
MATERIALS AND METHODS: We retrospectively evaluated 248 patients who had been referred for planning sonography at our department between October 2005 and February 2006. We reviewed the radiologic reports of 256 planning sonography examinations in terms of the rate of feasible cases and the reasons for infeasibility. The reasons for infeasibility were classified in six categories: an inconspicuous tumor, an inadequate electrode path, an organ vulnerable to collateral thermal damage, a tumor that was too large or too many tumors, and a high risk of the heat sink effect. In addition, we assessed the treatment modality for the patients who were determined to have HCCs for which percutaneous radiofrequency ablation was not feasible.
RESULTS: In 141 (55%) of the 256 planning sonography examinations, percutaneous radiofrequency ablation was feasible. The remaining 115 (45%) planning sonography examinations revealed that radiofrequency ablation was not a feasible procedure. The reasons for infeasibility included an inconspicuous tumor in 77 patients (55.8%), an inadequate electrode path in 33 patients (23.9%), an organ vulnerable to collateral thermal damage in 14 patients (10.1%), a tumor that was too large or too many tumors in eight patients (5.8%), a high risk of the heat sink effect in five patients (3.6%), and a portal vein thrombosis in one patient (0.7%). One reason for infeasibility was found in 96 patients, two reasons in 19 patients, and four reasons in one patient. Seventy (61.9%) of 113 patients for whom radiofrequency ablation was not feasible underwent transcatheter arterial chemoembolization as an alternative treatment.
CONCLUSION: In approximately half of the patients for whom percutaneous radiofrequency ablation of HCC is requested, the procedure is not feasible, mainly due to inconspicuous tumors, at planning sonography. Additional objective criteria for assessing the feasibility of radiofrequency ablation and therapeutic strategies according to the reasons for infeasibility should be investigated further.

Entities:  

Mesh:

Year:  2008        PMID: 18430851     DOI: 10.2214/AJR.07.2970

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  27 in total

1.  Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images.

Authors:  Haruyuki Takaki; Koichiro Yamakado; Atsuhiro Nakatsuka; Tomomi Yamada; Junji Uraki; Masataka Kashima; Takashi Yamanaka; Katsuya Shiraki; Yoshiyuki Takei; Kan Takeda
Journal:  Int J Clin Oncol       Date:  2011-10-22       Impact factor: 3.402

2.  Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Yoshiyuki Kobayashi; Kazuhiro Saito; Hirohito Takeuchi; Saori Ogawa; Mayumi Ando; Takatomo Sano; Toshifumi Mori; Yoshihiro Furuichi; Ikuo Nakamura
Journal:  Jpn J Radiol       Date:  2015-06-02       Impact factor: 2.374

3.  Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts.

Authors:  Masaya Miyazaki; Toshihiro Iguchi; Haruyuki Takaki; Takashi Yamanaka; Yoshitaka Tamura; Hiroyuki Tokue; Yozo Sato; Osamu Ikeda; Tadashi Shimizu; Koichiro Yamakado
Journal:  Jpn J Radiol       Date:  2016-07-23       Impact factor: 2.374

4.  Comparison of Laparoscopic Microwave to Radiofrequency Ablation of Small Hepatocellular Carcinoma (≤3 cm).

Authors:  Roberto Santambrogio; Jason Chiang; Matteo Barabino; Franca Maria Meloni; Emanuela Bertolini; Fabio Melchiorre; Enrico Opocher
Journal:  Ann Surg Oncol       Date:  2016-08-31       Impact factor: 5.344

5.  Clinical impact of cone beam computed tomography on iterative treatment planning during ultrasound-guided percutaneous ablation of liver malignancies.

Authors:  Chiara Floridi; Alessandro Radaelli; Filippo Pesapane; Enrico Maria Fumarola; Michela Lecchi; Andrea Agostini; Andrea Giovagnoni; Gianpaolo Carrafiello; Bradford Wood
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

6.  Thermal ablation with fusion imaging guidance of hepatocellular carcinoma without conspicuity on conventional or contrast-enhanced US: surrounding anatomical landmarks matter.

Authors:  Marco Calandri; Valeria Ruggeri; Patrizia Carucci; Stefano Mirabella; Andrea Veltri; Paolo Fonio; Carlo Gazzera
Journal:  Radiol Med       Date:  2019-07-03       Impact factor: 3.469

7.  Real-time contrast-enhanced ultrasound-guided biopsy of focal hepatic lesions not localised on B-mode ultrasound.

Authors:  Soon Ho Yoon; Kyoung Ho Lee; So Yeon Kim; Young Hoon Kim; Jee Hyun Kim; Sang Hyub Lee; Tae Kyoung Kim
Journal:  Eur Radiol       Date:  2010-03-23       Impact factor: 5.315

8.  Two-dimensional ultrasound-computed tomography image registration for monitoring percutaneous hepatic intervention.

Authors:  Robert M Pohlman; Michael R Turney; Po-Hung Wu; Christopher L Brace; Timothy J Ziemlewicz; Tomy Varghese
Journal:  Med Phys       Date:  2019-05-06       Impact factor: 4.071

9.  Contrast enhanced ultrasound guided biopsies of liver lesions not visualized on standard B-mode ultrasound-preliminary experience.

Authors:  Sasan Partovi; Ziang Lu; Rivka Kessner; Alice Yu; Yasmine Ahmed; Indravadan J Patel; Dean A Nakamoto; Nami Azar
Journal:  J Gastrointest Oncol       Date:  2017-12

10.  Assessing the value of volume navigation during ultrasound-guided radiofrequency- and microwave-ablations of liver lesions.

Authors:  Philippa Meershoek; Nynke S van den Berg; Jacob Lutjeboer; Mark C Burgmans; Rutger W van der Meer; Catharina S P van Rijswijk; Matthias N van Oosterom; Arian R van Erkel; Fijs W B van Leeuwen
Journal:  Eur J Radiol Open       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.